U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.32 (-1.58%)
     
  • Nasdaq

    14,030.38
    -131.02 (-0.93%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    -0.14 (-0.20%)
     
  • Gold

    1,763.90
    -5.10 (-0.29%)
     
  • Silver

    25.84
    -0.12 (-0.48%)
     
  • EUR/USD

    1.1862
    -0.0048 (-0.40%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3801
    -0.0123 (-0.88%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,965.50
    +107.48 (+0.30%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.22 (-0.19%)
     

MESO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 7, 2020 in the Class Action Filed on Behalf of Mesoblast Limited Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - December 7, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) alleging that the Company violated federal securities laws.

Class Period: April 16, 2019 and October 1, 2020
Lead Plaintiff Deadline: December 7, 2020

Learn more about your recoverable losses in MESO:
http://www.kleinstocklaw.com/pslra-1/mesoblast-limited-loss-submission-form?id=11405&from=5

The filed complaint alleges that Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders have until December 7, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the MESO lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69687